Aktis Oncology

Aktis Oncology is a biotechnology company dedicated to the discovery and development of novel targeted radiopharmaceuticals for the treatment of a wide range of solid tumor cancers. Founded and incubated by MPM Capital and its team of experienced entrepreneurs and drug developers, Aktis has created a proprietary platform to produce radiation therapies with optimized performance characteristics for tumor-targeted drugs. Designed for high penetration and extended retention, Aktis Oncology’s molecules can quickly clear from other areas of the body, maximizing tumor elimination while minimizing side effects of treatment. These therapies also enable clinicians to visualize and validate targets prior to exposure to therapeutic radioisotopes.